Javascript must be enabled to continue!
Factors influencing uptake of risk-reducing mastectomy among unaffected Israeli BRCA1/BRCA2 pathogenic variant carriers
View through CrossRef
Abstract
Women harboring pathogenic variant (PV) in the
BRCA1
or
BRCA2
genes (=
BRCA
) have an elevated lifetime risk for breast cancer (BC). One of the main options for active breast cancer risk reduction is bilateral risk-reducing mastectomy (RRM). Understanding the factors influencing that decision is important for genetic-counselling and risk mitigation strategy planning. A structured questionnaire was circulated to
BRCA
carriers, members of the Good Genes NGO in Israel. Data on RRM uptake and timing, factors previously reported to be associated with decision to undergo RRM (e.g., psychosocial, family history, counselling/health-system factors) were obtained. Comparison between carriers who elected to undergo RRM with those who opted for early detection schemes were performed using logistic regression and chi square statistical analyses. Of cancer free women (n = 391), 272 (69.6%) elected to adhere to the recommended surveillance scheme and 119 (30.4%) elected to undergo RRM. The major reasons for electing RRM over surveillance were active BC risk reduction (4.96 ± 0.23), fear of developing BC (4.86 ± 0.50), and having at least one relative with BC diagnosed under age 45 years. Support group discussions emerged as a stronger determinant of RRM uptake than primary care physician or religious guidance. In conclusion, among healthy Israeli
BRCA
carriers the decision to undergo RRM was influenced by a complex interplay of factors – active BC risk reduction, fear of cancer diagnosis in the context of having one relative with early onset BC and support group discussions were the major drivers of RRM in Israeli
BRCA1
carriers.
Springer Science and Business Media LLC
Title: Factors influencing uptake of risk-reducing mastectomy among unaffected Israeli BRCA1/BRCA2 pathogenic variant carriers
Description:
Abstract
Women harboring pathogenic variant (PV) in the
BRCA1
or
BRCA2
genes (=
BRCA
) have an elevated lifetime risk for breast cancer (BC).
One of the main options for active breast cancer risk reduction is bilateral risk-reducing mastectomy (RRM).
Understanding the factors influencing that decision is important for genetic-counselling and risk mitigation strategy planning.
A structured questionnaire was circulated to
BRCA
carriers, members of the Good Genes NGO in Israel.
Data on RRM uptake and timing, factors previously reported to be associated with decision to undergo RRM (e.
g.
, psychosocial, family history, counselling/health-system factors) were obtained.
Comparison between carriers who elected to undergo RRM with those who opted for early detection schemes were performed using logistic regression and chi square statistical analyses.
Of cancer free women (n = 391), 272 (69.
6%) elected to adhere to the recommended surveillance scheme and 119 (30.
4%) elected to undergo RRM.
The major reasons for electing RRM over surveillance were active BC risk reduction (4.
96 ± 0.
23), fear of developing BC (4.
86 ± 0.
50), and having at least one relative with BC diagnosed under age 45 years.
Support group discussions emerged as a stronger determinant of RRM uptake than primary care physician or religious guidance.
In conclusion, among healthy Israeli
BRCA
carriers the decision to undergo RRM was influenced by a complex interplay of factors – active BC risk reduction, fear of cancer diagnosis in the context of having one relative with early onset BC and support group discussions were the major drivers of RRM in Israeli
BRCA1
carriers.
Related Results
Abstract 1563: Damage-induced BRCA1 phosphorylation contributes to the timing of end resection
Abstract 1563: Damage-induced BRCA1 phosphorylation contributes to the timing of end resection
Abstract
Germline mutations of BRCA1 predispose women to breast and ovarian cancers. BRCA1 functions as a tumor suppressor. A wealth of evidence has established that...
Breast Cancer Susceptibility Gene 2 Deficiency Exacerbates Angiotensin‐II‐induced Endothelial Dysfunction and Apoptosis
Breast Cancer Susceptibility Gene 2 Deficiency Exacerbates Angiotensin‐II‐induced Endothelial Dysfunction and Apoptosis
Background
Germ‐line mutations in the tumour suppressor genes BRCA1 and BRCA2 (
BR
east
...
Abstract 1858: BRCA1 and BRCA2 sequence variants in Algerian breast/ovarian cancer families
Abstract 1858: BRCA1 and BRCA2 sequence variants in Algerian breast/ovarian cancer families
Abstract
Abstract: Background: Breast cancer is currently the leading cause of cancer morbidity and mortality among Algerian women. To date, very few reports have be...
Abstract 1451: BRCA1 and BRCA2 germline mutational spectrum in Algerian triple negative breast cancer (TNBC) patients
Abstract 1451: BRCA1 and BRCA2 germline mutational spectrum in Algerian triple negative breast cancer (TNBC) patients
Abstract
Background: Breast cancer is currently the leading cause of cancer morbidity and mortality among Algerian women. To date, triple negative breast cancer (TNB...
Abstract 5613: Unclassified variants and missense polymorphisms in BRCA1 and BRCA2 genes in Algerian breast/ovarian cancer families
Abstract 5613: Unclassified variants and missense polymorphisms in BRCA1 and BRCA2 genes in Algerian breast/ovarian cancer families
Abstract
Background: BRCA1 and BRCA2 germline mutations predispose heterozygous carriers to hereditary breast/ovarian cancer. Unclassified variants (UVs) and missens...
Abstract 1716: Evaluating the functional impacts of the BRCA1-mTORC2 interaction in breast cancer
Abstract 1716: Evaluating the functional impacts of the BRCA1-mTORC2 interaction in breast cancer
Abstract
Objective: The BRCA1 C-Terminal (BRCT) domain of BRCA1 has been found to interact with three accessory proteins (PRR5, RICTOR, and SIN1) of mTOR complex ...
Screening Breast MRI, Chemoprevention, and Risk-Reducing Surgeries in Unaffected BRCA Carriers.
Screening Breast MRI, Chemoprevention, and Risk-Reducing Surgeries in Unaffected BRCA Carriers.
Abstract
BACKGROUND: BRCA testing has identified hundreds of families with deleterious BRCA1 and BRCA2 mutations at the University of California, San Francisco (UCSF...
Review of the results of mass screening for the BRCA1/2 gene mutations in patients with different types of malignant neoplasms
Review of the results of mass screening for the BRCA1/2 gene mutations in patients with different types of malignant neoplasms
Background: germline mutations in the BRCA1 and BRCA2 genes are associated with a high risk of developing cancer of various localizations. Currently, the determination of BRCA stat...

